Clinical trial
Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer
NCT00466284 · Grupo Gallego de Cancer de Pulmon, Other · Unknown status
Key facts
| NCT number | NCT00466284 |
|---|---|
| Title | Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer |
| Lead sponsor | Grupo Gallego de Cancer de Pulmon, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Tarceva (erlotinib) |
| Enrollment | 46 |
| Start date | Jan 1, 2006 |
| First posted | Apr 27, 2007 |
| Last update posted | Apr 27, 2007 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: